Therapeutic strategies targeting specific IL-32 isoforms, such as using neutralizing antibodies, small molecule inhibitors, or gene editing technologies to regulate their expression or activity, could be developed to inhibit tumor development or enhance the immune system’s ability to fight against tumors. This evidence concerns the gene IL32 and neoplasm.